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Introduction
Trachoma, which is due to ocular infection with the intra-
cellular bacterium Chlamydia trachomatis, is the leading 
infectious cause of blindness worldwide. The discovery that 
ocular C. trachomatis infection can be successfully treated 
with a single, oral dose of azithromycin marked a significant 
advance in trachoma control.1 Today, mass drug administra-
tion (MDA) with azithromycin is a key component of a mul-
tifaceted strategy designed to control all phases of trachoma 
and recommended by the World Health Organization (WHO): 
the SAFE strategy, where S stands for surgery for trichiasis; 
A, for antibiotics to reduce the reservoir of C. trachomatis 
infection; F, for facial cleanliness to reduce transmission from 
ocular and nasal secretions; and E, for environmental improve-
ments to interrupt transmission of the bacterium and prevent 
re-emergence of the infection.2,3
Current WHO guidelines suggest that three annual 
rounds of azithromycin MDA should be completed before 
the prevalence of trachoma is reassessed.4 However, evidence 
from the Gambia and the United Republic of Tanzania in-
dicates that three rounds are unnecessary in low prevalence 
settings.5–8 In such situations, repeated azithromycin MDA 
may be detrimental if it results in the selection of macrolide-
resistant pathogens. Although currently there is no evidence 
that repeated MDA increases the prevalence of azithromycin-
resistant C. trachomatis,9 there is epidemiological evidence 
suggesting that pharyngeal carriage of macrolide-resistant 
Streptococcus pneumoniae increases following repeated MDA 
for trachoma control.10,11 Because S. pneumoniae is a leading 
cause of childhood mortality, especially in Africa, and because 
asymptomatic nasopharyngeal carriage is the initial step in the 
pathogenesis of pneumococcal disease, increased carriage of 
macrolide-resistant strains is a public health concern.
The Gambia, which is situated in western Africa and is in 
the Sahel belt, has seen a decline in the prevalence of follicular 
trachoma in children in recent decades: the prevalence (ad-
justed for the 1- to 9-year-old age group) derived from national 
surveys fell from 20% in 1986 to 7% in 1996.12,13 The country’s 
National Eye Health Programme, which was established in 
1986, has implemented all aspects of the SAFE strategy.14 
An evaluation of the implementation of SAFE interventions 
indicated that Gambian households have good access to water 
and latrines but a low awareness of community health educa-
tion programmes that promote face washing.15 Recent survey 
work carried out in four health districts following the national 
azithromycin MDA campaign that ran from 2007 to 2010 sug-
gests that the prevalence of follicular trachoma in the country 
is now nearing 5%, which is the threshold for elimination.8
The Partnership for the Rapid Elimination of Trachoma 
(PRET) study was a cluster randomized trial embedded within 
the Gambia’s MDA campaign that compared the prevalence of 
active trachoma in Gambian communities which had received 
azithromycin annually for three years with that in communi-
ties which received a single treatment round.8 The aim of the 
present study was to determine whether the nasopharyngeal 
Objective To evaluate the effect of repeated mass drug administration (MDA) of azithromycin in the Gambia on the nasopharyngeal carriage 
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carriage of azithromycin-resistant 
S. pneumoniae was more prevalent in 
communities that received three MDA 
rounds than in those that received one. 
We considered only data from villages 
in which children had been vaccinated 
with a 7-valent pneumococcal conjugate 
vaccine (PCV-7) because we wanted our 
results to be relevant to the increasing 
number of African countries that in-
clude these vaccines in their vaccination 
schedules.
Methods
The study included the residents of eight 
villages in a rural region of western 
Gambia where the population predomi-
nantly comprises subsistence farmers 
who grow millet and maize for home 
consumption and groundnuts as a cash 
crop. The people belong mainly to the 
Jola and Mandinka ethnic groups. The 
climate of the Gambia is tropical and 
there is one rainy season, lasting from 
June to October.
All study villages had participated 
in a cluster randomized trial of the 
impact of PCV-7 on pneumococcal 
nasopharyngeal carriage that ran from 
July 2006 to July 2008.16 All children 
who were under the age of 30 months 
when the vaccine trial started, who were 
born during the trial period or who 
moved into a study village during the 
trial period received PCV-7.16 In Au-
gust 2009, PCV-7 was introduced into 
the Gambian Expanded Programme on 
Immunization.
The PRET study was a cluster ran-
domized, controlled trial whose design 
has been described elsewhere.8,17 Briefly, 
enumeration areas with a population of 
600 to 800 individuals were randomized 
either to receive MDA with azithromy-
cin annually for three years or to have 
treatment discontinued if the prevalence 
of either active trachoma or ocular 
C. trachomatis infection in children 
aged 5 years or younger fell below 5% 
(i.e. the stopping rule). Six months after 
the first MDA round, the prevalence of 
active trachoma and of C. trachomatis 
infection in communities randomized 
to the stopping rule were 2.4% and 0%, 
respectively, and MDA therefore ceased 
in all those communities.8
Our study comprised two treatment 
arms and involved only villages in which 
children had received PCV-7 (Fig. 1). 
The first arm included two villages that 
had been randomized to three annual 
MDA rounds. Three cross-sectional sur-
veys were conducted in these villages: 
the first took place 11 months after the 
second MDA round, the second took 
place 1 month after the third MDA 
round and the third took place 6 months 
after the third MDA round. The second 
arm included six villages that had been 
randomized to the stopping rule and 
where MDA had been carried out only 
once. In these villages, one cross-sec-
tional survey was conducted 30 months 
after the single MDA round – it took 
place at the same time as the third cross-
sectional survey in villages that received 
three MDA rounds (Fig. 1).
Census data were gathered in the 
week before the first cross-sectional 
survey. All children under the age of 
15 years who were included in the cen-
sus and who were present at the time of 
the survey were invited to participate. In 
addition, 150 individuals aged 15 years 
or more were randomly selected to par-
ticipate in each cross-sectional survey, 
including the single survey conducted 
in villages randomized to the stopping 
rule. Although random selection was 
carried out independently for each 
survey, the second and third surveys 
in villages that received three MDA 
rounds included only individuals who 
had received azithromycin during the 
third MDA round in July 2010.
During each survey, a questionnaire 
was administered and a nasopharyngeal 
specimen was taken from each par-
ticipant by means of a calcium alginate 
swab, which was then inoculated in a 
transport medium of skimmed milk, 
tryptone, glucose and glycerol in a sterile 
vial. In the field, the samples were kept 
on wet ice. They were transferred to a 
refrigerator set to 4 °C within 8 hours 
of collection and moved to long-term 
storage at −70 °C within 24 hours of 
collection. 
For analysis, the nasopharyngeal 
swab samples were thawed at room 
temperature and 10 μL of the transport 
medium was inoculated onto Columbia 
agar supplemented with 5% sheep’s 
blood and 5 μg/mL of gentamicin. The 
agar plates were then incubated for 18 to 
24 hours at 35 °C in an atmosphere con-
taining 5% carbon dioxide. Presumptive 
S. pneumoniae colonies were identified 
on the basis of their morphology and 
optochin sensitivity and the presence 
of S. pneumoniae was confirmed using a 
Fig. 1. Flowchart for the study of the effect of mass azithromycin administration on 
nasopharyngeal carriage of Streptococcus pneumoniae, Gambia, 2008–2010
2 villages 
715/799 residents treated 
(89.5%)
2 villages 
750/927 residents treated 
(80.9%)
2 villages 
774/1013 residents 
treated (76.4%)
Survey 1a
415 residents sampled
Jun 2010
Survey 2b
417 residents sampled
Jul 2010
Survey 3c
343 residents sampled
Dec 2010
Survey 3c
400 residents sampled
Dec 2010
6 villages 
1019/1124 residents 
treated (90.3%)
8 villages
MDA round 1
Jul–Aug 2008
MDA round 2
Jul–Aug 2009
MDA round 3
Jul 2010
MDA: mass drug administration.
a  The first cross-sectional survey was carried out 11 months after the second azithromycin MDA round in 
villages that took part in three rounds.
b  The second survey was carried out 1 month after the third MDA round.
c  The third survey was carried out 6 months after the third MDA round in villages that took part in three 
rounds and, at the same time, 30 months after the single MDA round in villages that received only one 
round.
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polymerase chain reaction (PCR) tech-
nique that targeted the cpsA gene.18 The 
density of nasopharyngeal carriage was 
scored semiquantitatively as previously 
described.19 For each nasopharyngeal 
swab sample, up to four S. pneumoniae 
colonies with different morphologies 
were screened by disc diffusion for 
their sensitivity to azithromycin. The 
minimal inhibitory concentration of 
azithromycin was determined using 
the Etest (Biomerieux, Marcy l’Etoile, 
France) in isolates with an intermediate 
or resistant phenotype. Nasopharyngeal 
swab samples that tested positive for S. 
pneumoniae were serotyped using a mul-
tiplex PCR assay optimized for African 
clinical samples.20 Colonies were scraped 
from the first quadrant of the agar plate 
and total, genomic DNA was extracted 
using the QIAamp DNA Minikit (Qia-
gen, Hilden, Germany) according to the 
manufacturer’s instructions. The primer 
concentrations and cycling conditions 
were as recommended by the United 
States Centers for Disease Control and 
Prevention protocol.20
Statistical analysis
Data were double-entered into an 
OpenClinica database (OpenClinica, 
Waltham, United States of America). 
Differences between survey samples 
and between treatment groups in the 
proportion of patients who carried any 
pneumococci or azithromycin-resistant 
pneumococci were evaluated using 
Fisher’s exact test. In addition, logistic 
regression analysis was used to identify 
risk factors for pneumococcal carriage, 
to control for confounders and to test for 
interactions. The results were reported 
in terms of odds ratios (ORs) and 95% 
confidence intervals (CIs). Both CIs and 
P-values were estimated using clustered 
(by village) robust standard errors.
The primary analysis considered the 
overall prevalence of pneumococcal na-
sopharyngeal carriage and the second-
ary analysis considered the prevalence 
of the carriage of azithromycin-resistant 
strains (i.e. those with a minimal inhibi-
tory concentration of azithromycin of 
16 μg/mL or more) and of individual 
serotypes and serotype groups. Five se-
rotype groups were investigated: (i) the 
most frequent serotypes, which were 
defined as those detected in at least 10 
individuals; (ii) PCV-7 serotypes, which 
included pneumococcal serotypes 4, 6B, 
9V, 14, 18C, 19F and 23F, and serotypes 
6A and 6C; (iii) serotypes not in PCV-7, 
which included any other pneumococcal 
serotypes detectable by the multiplex 
PCR method; (iv) paediatric serotypes, 
which were defined as serotypes 4, 6, 
7, 9, 14, 18, 19 and 23;21 and (v) non-
serotypeable pneumococci. All P-values 
were adjusted for multiple testing using 
the Benjamini and Hochberg false dis-
covery rate procedure. Fisher’s exact test 
was used to evaluate heterogeneity in the 
serotype distribution between villages.
This study adhered to the tenets 
of the Declaration of Helsinki and was 
approved by the Gambian Government/
Medical Research Council Unit and the 
Gambia Joint Ethics Committee. Writ-
ten, informed consent was freely ob-
tained from all participants of the PRET 
trail and additional written consent was 
obtained from participants in our ancil-
lary study. For minors, informed consent 
was obtained from a parent or guardian.
Results
The first cross-sectional survey collected 
data on 415 individuals from villages 
that took part in three azithromycin 
MDA rounds and the second survey col-
lected data on 417 similar individuals. 
The third survey included a total of 743 
participants: 343 from villages that took 
part in three MDA rounds and 400 from 
villages randomized to the stopping rule 
Table 1. Participants in study of the effect of mass azithromycin administration on 
nasopharyngeal carriage of Streptococcus pneumoniae, Gambia, 2010
Characteristic No. (%) of participants in villages exposed to  
three MDA rounds
No. (%) of 
participants 
in villages 
exposed to one 
MDA roundd
First surveya Second surveyb Third surveyc
All participants 415 (100) 417 (100) 343 (100) 400 (100)
Age, years
< 10 205 (49.4) 173 (41.5) 182 (53.1) 182 (45.5)
≥ 10 210 (50.6) 244 (58.6) 161 (46.9) 218 (54.5)
Sex
Male 219 (52.8) 209 (50.1) 158 (46.1) 211 (52.8)
Jola ethnicity 409 (98.6) 407 (97.6) 333 (97.1) 369 (92.3)
Occupation
None 185 (45.1) 162 (39.0) 169 (50.0) 155 (40.9)
Student 149 (36.3) 149 (35.9) 90 (26.6) 133 (35.1)
Agricultural 
worker
76 (18.5) 104 (25.1) 79 (23.4) 91 (24.0)
Other 5 (1.2) 2 (0.5) 5 (1.5) 21 (5.3)
Schooling, 
years
0 260 (62.7) 258 (61.9) 242 (71.8) 260 (65.0)
1–3 73 (17.6) 67 (16.1) 36 (10.7) 63 (15.8)
4–6 51 (12.3) 48 (11.5) 25 (7.4) 11 (2.8)
> 6 31 (7.5) 44 (10.6) 34 (10.1) 66 (16.5)
Able to read 156 (37.6) 158 (37.9) 56 (16.3) 76 (19.0)
Able to write 155 (37.4) 158 (37.9) 63 (18.4) 94 (23.5)
Recente health 
visit
14 (3.4) 12 (2.9) 30 (8.8) 19 (4.8)
Recente 
antibiotic use
2 (0.5) 2 (0.5) 4 (1.2) 6 (1.5)
Smoker 20 (4.8) 12 (2.9) 13 (3.8) 13 (3.3)
Smoker in 
household
265 (63.9) 273 (65.4) 166 (48.7) 121 (30.3)
MDA: mass drug administration.
a  The first survey was carried out 11 months after the second MDA round.
b  The second survey was carried out 1 month after the third MDA round.
c  The third survey was carried out 6 months after the third MDA round.
d  Only the third survey was carried out in villages that received a single MDA round – 30 months after MDA, 
at the same time as the third survey in villages that took part in three MDA rounds.
e  Within the last 30 days.
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and that took part in one round (Fig. 1). 
The demographic characteristics of the 
participants sampled in each survey are 
listed in Table 1.
Table 2 reports the overall preva-
lence of nasopharyngeal S. pneumoniae 
carriage in individuals from villages that 
took part in three MDA rounds. In the 
first survey, 11 months after the second 
MDA round, the prevalence was 43.4%. 
By the second survey, 1 month after 
the third MDA round, the prevalence 
had decreased significantly, to 19.2%. 
However, by the third survey, 6 months 
after the third MDA round, it was 45.8%, 
similar to the initial level. In each survey, 
the prevalence of nasopharyngeal car-
riage was lower among individuals aged 
10 years or older than among younger 
individuals. Table 3 shows that, in the 
third survey, there was no significant dif-
ference in prevalence between individu-
als from villages that took part in three 
MDA rounds and those from villages 
that took part in one: the prevalence was 
45.8% and 50.3% in the two treatment 
arms, respectively.
No evidence of pneumococcal 
azithromycin resistance was found in 
the first cross-sectional survey among 
individuals from villages that took part 
in three MDA rounds. The prevalence 
of the pneumococcal nasopharyngeal 
carriage of azithromycin-resistant 
isolates among sampled individuals 
rose to 1.2% in the second survey but 
decreased to 0.9% in the third (Table 4). 
In the third survey, the prevalence of 
the carriage of azithromycin-resistant 
strains was similar in individuals from 
villages that took part in three MDA 
rounds and in those from villages that 
took part in one: 0.9% versus 0.3%, 
respectively (Table 4).
Serotyping of pneumococci isolated 
in the third survey showed no significant 
difference in the prevalence of the car-
riage of PCV-7 serotypes between the 
treatment arms (Table 5). Nor was there 
a significant difference in the prevalence 
of serotypes not in PCV-7, of paediatric 
serotypes or of non-serotypeable pneu-
mococci. However, the prevalence of se-
rotypes 15B and/or 15C was significantly 
higher in individuals from villages that 
took part in three MDA rounds than 
in those from villages that took part 
in one (9.0% versus 2.3%, respectively; 
P = 0.001); the prevalence of serotype 
10A was also higher (6.1% versus 0.6%, 
respectively; P < 0.001), whereas that of 
serotype 35B was lower (1.2% versus 
4.5%, respectively; P = 0.031; Table 5). 
The distribution of serotype 10A in 
villages that took part in three MDA 
rounds was significantly heterogeneous 
(P = 0.012), as was the distribution of 
serotype 35B in villages that took part 
in one round (P = 0.006). By contrast, 
there was no significant difference in 
the distribution of serotypes 15B and/or 
15C between the two villages that took 
part in three MDA rounds (P = 0.348), 
which provides further evidence for the 
existence of a difference between the two 
treatment arms.
Further analysis indicated that 
individuals who were S. pneumoniae 
carriers in the first cross-sectional 
survey were significantly more likely 
than those who were not to be carriers 
in the second survey (adjusted OR, 
aOR: 3.71; Table 6). However, there was 
no significant association between the 
density of carriage at the first survey 
and carriage at the second survey: the 
aOR for carriage at the second survey 
for high-density versus low-density 
carriage at the first survey was 1.09 
(95% CI: 0.66–1.80). In the second 
survey, pneumococcal carriage was 
less likely in participants aged 10 years 
or older than in younger children 
(aOR: 0.33) and less likely in students 
(aOR: 0.24) and agricultural workers 
(aOR: 0.32) than in individuals with 
no occupation (Table 6).
Table 2. Prevalence of nasopharyngeal Streptococcus pneumoniae carriage in individuals 
from villages exposed to three mass azithromycin administration rounds, by 
survey, Gambia, 2010
Age of 
survey 
partici-
pants
Cross-
sectional 
survey
No. of 
survey 
participants
No. (%) of  
S. pneumoniae 
carriers
Crude OR 
(95% CI)
Adjusted ORa 
(95% CI)
< 10 years Firstb 205 124 (60.5) 1.0 1.0
Secondc 173 61 (35.3) 0.35 (0.23–0.53) 0.35 (0.23–0.53)
Thirdd 182 116 (63.7) 1.14 (0.75–1.73) 1.14 (0.75–1.73)
≥ 10 years Firstb 210 56 (26.7) 1.0 1.0
Secondc 244 19 (7.8) 0.22 (0.13–0.39) 0.23 (0.13–0.40)
Thirdd 161 41 (25.5) 0.91 (0.57–1.47) 0.96 (0.59–1.55)
All Firstb 415 180 (43.4) 1.0 1.0
Secondc 417 80 (19.2) 0.30 (0.22–0.41) 0.30 (0.22–0.42)
Thirdd 343 157 (45.8) 1.09 (0.82–1.46) 1.09 (0.80–1.48)
CI: confidence interval; MDA: mass drug administration; OR: odds ratios.
a  The OR was adjusted for age and sex and the within-village correlation of participants was taken into 
account using clustered robust standard errors.
b  The first survey was carried out 11 months after the second MDA round.
c  The second survey was carried out 1 month after the third MDA round.
d  The third survey was carried out 6 months after the third MDA round.
Table 3. Prevalence of nasopharyngeal Streptococcus pneumoniae carriage at the third 
survey,a by azithromycin treatment, Gambia, 2010
Age of 
survey 
participants
No. of 
MDA 
rounds
No. of survey 
participants
No. (%) of  
S. pneumoniae 
carriers
Crude OR 
(95% CI)
Adjusted ORb 
(95% CI)
< 10 years 1 182 136 (74.7) 1.0 1.0
3 182 116 (63.7) 0.59 (0.29–1.17) 0.59 (0.30–1.17)
≥ 10 years 1 218 65 (29.8) 1.0 1.0
3 161 41 (25.5) 0.72 (0.36–1.5) 0.69 (0.34–1.39)
All 1 400 201 (50.3) 1.0 1.0
3 343 157 (45.8) 0.77 (0.41–1.44) 0.65 (0.35–1.20)
CI: confidence interval; OR: odds ratios; MDA: mass drug administration.
a  The third survey was carried out 6 months after the third mass drug administration round.
b  The OR was adjusted for age and sex and the within-village correlation of risk factors was taken into 
account using clustered robust standard errors.
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Discussion
In communities where the initial preva-
lence of pneumococcal nasopharyngeal 
carriage was high but the prevalence of 
the carriage of azithromycin-resistant 
strains was low, we observed that receiv-
ing three annual azithromycin MDA 
rounds was associated with a short-term 
decrease in pneumococcal carriage that 
was not accompanied by a significant 
increase in azithromycin resistance. 
There was no evidence of azithromycin 
resistance at the first cross-sectional 
survey in communities that received 
two MDA rounds. Moreover, since a 
previous study carried out in the same 
geographical area showed no evidence 
of erythromycin resistance in individu-
als carrying pneumococcus,22 we did 
not expect macrolide-resistant strains 
to be circulating before treatment. The 
absence of azithromycin resistance at the 
first cross-sectional survey is consistent 
with previous studies carried out in Aus-
tralia, Nepal and the United Republic 
of Tanzania, all of which showed that 
substantial azithromycin resistance did 
not develop following a single treat-
ment dose in areas where the baseline 
prevalence of the carriage of resistant 
strains was low.23–25 The prevalence of 
the carriage of azithromycin-resistant 
pneumococci rose to just over 1% at the 
second cross-sectional survey. However, 
at the third survey, there was no signifi-
cant difference in prevalence between 
villages that received three annual MDA 
rounds and those that received one.
In contrast to our findings, a study 
carried out in central areas of the 
United Republic of Tanzania reported 
that a single MDA round significantly 
increased the prevalence of azithro-
mycin resistance, which was detectable 
6 months later.26 In that study, azithro-
mycin-resistant pneumococcal strains 
Table 4. Prevalence of nasopharyngeal azithromycin-resistant Streptococcus pneumoniae carriage, by azithromycin treatment and 
survey, Gambia, 2010
No. of MDA 
rounds
Cross-
sectional 
survey
Survey participants
Aged < 10 years Aged ≥ 10 years All
No. of survey 
participants
No. (%) of 
carriersa
Pb No. of survey 
participants
No. (%) of 
carriersa
Pb No. of survey 
participants
No. (%) of 
carriersa
Pb
Between-survey 
comparison
3 Firstc 205 0 (0) 0.200 210 0 (0) 0.119 415 0 (0) 0.066
3 Secondd 173 2 (1.2) – 244 3 (1.2) – 417 5 (1.2)
3 Thirde 182 3 (1.7) – 161 0 (0) – 343 3 (0.9)
Between-treatment 
comparison
1 Thirde 182 1 (0.6) 0.311 218 0 (0) NA 400 1 (0.3) 0.340
3 Thirde 182 3 (1.7) – 161 0 (0) – 343 3 (0.9)
MDA: mass drug administration; NA: not applicable.
a  Carriers of azithromycin-resistant Streptococcus pneumonia.
b  Differences between survey samples and between treatment groups were evaluated using Fisher’s exact test.
c  The first survey was carried out 11 months after the second MDA round in villages that took part in three rounds.
d  The second survey was carried out 1 month after the third MDA round.
e  The third survey was carried out 6 months after the third MDA round in villages that took part in three rounds and, at the same time, 30 months after the single MDA 
round in villages that had received one round.
Table 5. Prevalence of carriage of Streptococcus pneumoniae serotypes, by azithromycin 
treatment, Gambia, 2010
S. pneumoniae serotype No. (%) of serotype carriers from villages Pa
exposed to 1 MDA 
round (n = 400)
exposed to 3 MDA 
rounds (n = 343)
16F 35 (8.8) 22 (6.4) 0.426
15B and/or 15Cb 9 (2.3) 31 (9.0) 0.001
6A, 6B and/or 6Cc 21 (5.3) 14 (4.1) 0.667
3 19 (4.8) 8 (2.3) 0.241
34 12 (3.0) 12 (3.5) 0.962
19A 12 (3.0) 10 (2.9) 1.000
35B 18 (4.5) 4 (1.2) 0.031
10A 1 (0.6) 21 (6.1) < 0.001
19F 8 (2.0) 11 (3.2) 0.539
23B 8 (2.0) 5 (1.5) 0.927
14 8 (2.0) 4 (1.2) 0.586
PCV-7 serotypesd 48 (12.0) 38 (11.1) 0.896
Non-vaccine serotypese 206 (51.5) 161 (46.9) 0.395
Paediatric serotypesf 76 (19.0) 53 (15.5) 0.360
Non-serotypeable 
pneumococci
33 (8.3) 17 (5.0) 0.177
MDA: mass drug administration; PCV-7: 7-valent pneumococcal conjugate vaccine.
a  P-values were adjusted for multiple testing using the Benjamini and Hochberg false discovery rate 
procedure.
b  The polymerase chain reaction method used could not distinguish between serotypes 15B and 15C.
c  The polymerase chain reaction method used could not distinguish between serotypes 6A, 6B and 6C.
d  PCV-7 serotypes included serotypes 4, 6B, 9V, 14, 18C, 19F and 23F plus serotypes 6A and 6C.
e  Detectable serotypes not in PCV-7.
f  Paediatric serotypes included serotypes 4, 6, 7, 9, 14, 18, 19 and 23.
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were present in the community before 
treatment: 2.1% of pneumococcal strains 
isolated at baseline were resistant. Six 
months after the single MDA round, 
the proportion of resistant isolates was 
35%. Since, in our study, we did not 
collect samples 6 months after MDA in 
areas that received a single MDA round, 
we cannot directly compare our results 
with those of the Tanzanian study and 
we cannot say what the immediate ef-
fect of a single MDA round was in the 
Gambian population. However, as we 
did not observe azithromycin resistance 
6 months after the third MDA round in 
communities that received three rounds, 
it is unlikely that we would have ob-
served resistance 6 months after the first 
MDA round. In addition, the Tanzanian 
study also reported a large variation 
in the proportion of individuals with 
azithromycin-resistant pneumococci 
in the untreated study arm: it ranged 
from 4.4% to 13.1%. Another difference 
between the two studies was that 65% of 
the participants in the Tanzanian study 
reported taking unspecified drugs to 
treat suspected infections in the 30 days 
before baseline azithromycin treatment, 
whereas only 2% of the participants in 
our study reported recent antibiotic 
use at the first survey. Moreover, a sig-
nificant proportion of children in the 
Tanzanian study received amoxicillin 
for acute respiratory infections during 
the study period.
In the villages in our study that re-
ceived three MDA rounds and where the 
prevalence of pneumococcal carriage 
and rates of transmission were high,16,22 
the third MDA round decreased the 
prevalence of pneumococcal carriage 
from 43.4% at the first survey 11 months 
after the second MDA round to 19.2% 
at the second survey 1 month after the 
third round. However, this effect had 
already waned 6 months after treatment, 
by the time of the third survey. This 
short-lived reduction in pneumococcal 
nasopharyngeal carriage may, at least 
in part, explain the decrease in child 
mortality that has been reported fol-
lowing MDA in communities in Ethio-
pia27,28 since bacterial carriage is a proxy 
measure of invasive disease. Despite the 
significant reduction in the prevalence 
of pneumococcal carriage associated 
with the third MDA round, one month 
later, at the second survey, we were able 
to identify individuals who were pneu-
mococcal carriers and who could still, 
therefore, transmit pneumococcus to the 
community. Being a carrier in the first 
cross-sectional survey was a risk factor 
for being a carrier one month after the 
third MDA round. The other risk factors 
for carriage after treatment were similar 
to known risk factors for pneumococcal 
carriage and included young age – which 
is consistent with previous findings indi-
cating that children drive pneumococcal 
transmission.16,22
Serotype replacement is a concern 
in communities in which vaccines 
Table 6. Risk factors for nasopharyngeal carriage of Streptococcus pneumoniae at the 
second surveya among individuals from villages exposed to three rounds of 
mass azithromycin administration, Gambia, 2010
Characteristic No. of 
participantsa
No. (%) of 
carriers of  
S. pneumoniae
Unadjusted OR 
(95% CI)
Adjusted ORb 
(95% CI)
Carrier at first 
surveyc
No 154 15 (9.7) 1.0 1.0
Yes 124 45 (36.3) 5.28 (2.77–10.07) 3.71 (2.44–5.64)
Age
< 10 years 173 61 (35.3) 1.0
≥ 10 years 244 19 (7.8) 0.16 (0.12–0.20) 0.33 (0.28–0.38)
Occupation
None 162 63 (38.9) 1.0 1.0
Student 149 13 (8.7) 0.15 (0.06–0.37) 0.24 (0.07–0.86)
Agricultural worker 104 4 (3.9) 0.06 (0.04–0.10) 0.32 (0.30–0.34)
Sex
Male 209 39 (18.7) 1.0 NA
Female 208 41 (19.7) 1.07 (0.81–1.41) NA
Villaged
1 217 32 (14.8) 1.0 NA
2 200 48 (24.0) 1.83 (1.83–1.83) NA
Schooling, years
0 258 67 (26.0) 1.0 NA
1 67 8 (11.9) 0.39 (0.18–0.84) NA
2 48 2 (4.2) 0.12 (0.04–0.40) NA
≥ 3 44 3 (6.8) 0.21 (0.18–0.24) NA
Able to read
No 259 67 (25.9) 1.0 NA
Yes 158 13 (8.2) 0.26 (0.14–0.48) NA
Able to write
No 259 67 (25.9) 1.0 NA
Yes 158 13 (8.2) 0.26 (0.14–0.48) NA
Recente health visit
No 405 75 (18.5) 1.0 NA
Yes 12 5 (41.7) 3.14 (2.87–3.44) NA
Recente antibiotic 
use
No 415 79 (19.0) 1.0 NA
Yes 2 1 (50.0) 4.25 (0.15–
122.58)
NA
Smoker in 
household
No 144 28 (19.4) 1.0 NA
Yes 273 52 (19.1) 0.97 (0.57–1.66) NA
CI: confidence interval; MDA: mass drug administration; NA: not applicable; OR: odds ratio.
a  The second cross-sectional survey was carried out 1 month after the third MDA round.
b  The OR was adjusted for carriage of S. pneumoniae at the first cross-sectional survey, age and occupation.
c  The first survey was carried out 11 months after the second MDA round.
d  Individuals from two villages participated in the survey.
e  Within the last 30 days.
Bull World Health Organ 2014;92:490–498| doi: http://dx.doi.org/10.2471/BLT.13.133462496
Research
Azithromycin treatment and S. pneumoniae carriage in the Gambia Sarah E Burr et al.
摘要
阿奇霉素的集体服药和肺炎链球菌带菌：冈比亚横断面调查
目的 评估阿奇霉素在冈比亚的重复大规模药物治疗
（MDA）对肺炎链球菌鼻咽带菌和耐药菌株出现的影响。
方法 本研究涉及参加比较沙眼流行率一轮和三轮阿奇
霉素 MDA 效果集群随机试验的村庄。仅纳入其大多
数儿童接受 7 价肺炎球菌结合疫苗的村庄。对接受三
轮年度 MDA 的两个村庄进行三次横断面调查 ：在第
三轮 MDA 前不久完成第一次调查，第二次和第三次
调查分别在第三轮 MDA 之后的 1 个月和 6 个月进行。
第三次调查还涉及在 30 个月之前接受过一轮 MDA 的
六个村庄。使用鼻咽拭子评估肺炎球菌带菌，使用浓
度梯度法检测阿奇霉素耐药性。
结果 在第一次和第二次调查之间肺炎球菌带菌流行率
从 43.4% 下降至 19.2%（P < 0.001），但是到第三次调查
则有所反弹（45.8% ；P = 0.591）。第一次调查的携带者
是第二次调查中成为携带者的风险因素（优势比：3.71；
P <  0.001）。在第三次调查时，一轮和三轮 MDA 之后
صخلم
ايبماغ في تاعاطقلا ةددعتم حوسم :ةيوئرلا ةيدقعلا لاقتناو ييرهاجم قاطن لىع ينسيامورثيزلأا ءاود عيزوت
 قاطن  لىع  ينسيامورثيزلأا  ءاود  عيزوت  راركت  يرثأت  مييقت  ضرغلا
 موعلبلا  قيرط  نع  ةيوئرلا  ةيدقعلا  لاقتنا  لىع  ايبماغ  في  ييرهاجم
.ةيويلحا تاداضملل ةمواقم تلالاس روهظ لىعو يفنلأا
 ةبرتج في تكراش يتلا  ىرقلا  لىع ةساردلا  هذه تلمتشا ةقيرطلا
 نم تلاوج ثلاث لباقم ةدحاو ةلوج يرثأت نراقت ةيدوقنع ةيئاوشع
 راشتنا لدعم لىع ييرهاجم قاطن لىع ينسيامورثيزلأا ءاود عيزوت
 حاقللا الهافطأ مظعم ىقلت يتلا ىرقلا جاردإ طقف متو .اموخاترلا
 ةثلاث  ءارجإ  متو  .ةيوئرلا  تاروكملل  داضلما  يعابسلا  نراقتلما
 ةيونس  تلاوج  ثلاث  اتقلت  ينتيرق  في  تاعاطقلا  ةددعتم  حوسم
 حسلما يرجأ :ييرهاجم قاطن لىع ينسيامورثيزلأا ءاود عيزوت نم
 ينسيامورثيزلأا  ءاود  عيزوت  نم  ةثلاثلا  ةلولجا  لبق  ةشرابم  لولأا
 نم  رهشأ  ةتسو  رهش  دعب  ةثلاثلاو  ةيناثلاو  ييرهاجم  قاطن  لىع
 لىع ،ييرهاجم قاطن لىع ينسيامورثيزلأا ءاود عيزوتل ةثلاثلا ةلولجا
 عيزوت ةلوج تقلت ىرق تس كلذك ثلاثلا حسلما لمشو .لياوتلا
 متو  .ًارهش  ينثلاث  لبق  ييرهاجم  قاطن  لىع  ينسيامورثيزلأا  ءاود
 يفنلأا  موعلبلا  تاحسم  مادختساب  ةيوئرلا  ةيدقعلا  لاقتنا  مييقت
 سايقم  رابتخا  مادختساب  ينسيامورثيزلأا  ةمواقم  فاشتكا  متو
.نوليسبإ
 % 43.4  نم ةيوئرلا ةيدقعلا لاقتنا  راشتنا  لدعم ضفخنا جئاتنلا
 )0.001 < لماتحلاا(  نياثلاو  لولأا  ينحسلما  ينب  % 19.2  لىإ
 .)0.591 = لماتحلاا  ؛% 45.8(  ثلاثلا  حسلما  عم  دترا  هنكلو
 نياثلا حسلما في لقانك راطتخا لماع لولأا حسلما في لقانلا برتعاو
 راشتنا لدعم ناكو .)0.001  < لماتحلاا ؛3.71 :لماتحلاا ةبسن(
 تلاوج ثلاثو ةدحاو ةلوج دعب ًابهاشتم ثلاثلا حسلما في لاقتنلاا
 % 50.3(  ييرهاجم  قاطن  لىع  ينسيامورثيزلأا  ءاود  عيزوت  نم
 لدعم  عم  ،)0.170 = لماتحلاا  ؛لياوتلا  لىع  ،% 45.8  لباقم
 لىع  ،% 0.9  لباقم  % 0.3(  ينسيامورثيزلأا  ءاود  ةمواقم  راشتنا
.)0.340 = لماتحلاا ؛لياوتلا
 لىع ينسيامورثيزلأا ءاود عيزوتل ثلاثلا تلاولجا ِدؤت لم جاتنتسلاا
 ةيدقعلا  تلالاس  لاقتنا  راشتنا  لدعم  دايدزا  لىإ  ييرهاجم  قاطن
 ةنراقم يفنلأا موعلبلا  قيرط نع ينسيامورثيزلأل ةمواقلما  ةيوئرلا
ةدحاو ةلوجب
with limited valency have been used to 
protect against pneumococcal disease. 
However, our data suggest that azithro-
mycin MDA did not modify the carriage 
of the most prevalent S. pneumoniae 
serotypes, except for serotypes 15B and/
or 15C, which had a higher prevalence at 
the third survey in the two villages that 
received three MDA rounds than in vil-
lages that received one round. Moreover, 
the prevalence of the carriage of PCV-7 
serotypes was not affected by MDA.
One limitation of this study is the 
small number of villages included. This 
was a consequence of our decision to in-
clude only villages in which children had 
received PCV-7, as recommended by 
WHO,29 because we wanted our findings 
to be relevant to countries that include 
PCV-7 in their national immunization 
programmes. As a result, we selected 
villages that had participated in the 
PRET trial and in a trial of the impact of 
PCV-7 on pneumococcal nasopharyn-
geal carriage.16 Whether azithromycin 
would have had the same effect in the 
absence of PCV-7 vaccination cannot, 
therefore, be addressed directly by our 
study. However, if azithromycin has the 
same effect on all serotypes, as our data 
suggest, the initial serotype distribution 
in the population should not affect the 
outcome of treatment.
In summary, the high prevalence 
of pneumococcal carriage and the high 
pneumococcal transmission rate in 
our study population coupled with the 
administration of PCV-7 to young chil-
dren provided a unique opportunity to 
evaluate the effect of azithromycin MDA 
on pneumococcal nasopharyngeal car-
riage. We found that three MDA rounds, 
administered according to WHO guide-
lines, did not increase the prevalence of 
the carriage of azithromycin-resistant 
pneumococcal strains over the long term 
and that children played an important 
role in pneumococcal transmission in 
the community following azithromycin 
MDA. ■
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的带菌流行率（分别为 50.3% 和 45.8%；P = 0.170）相似，
阿齐霉素耐药流行率（分别为 0.3% 和 0.9% ；P = 0.340）
也相似。
结论 较之一轮治疗，三轮阿奇霉素 MDA 没有提高阿
奇霉素耐药肺炎球菌菌株鼻咽带菌的流行率。 
Résumé
Administration massive d’azithromycine et portage du Streptococcus pneumoniae: études transversales en Gambie
Objectif Évaluer l’effet de l’administration de médicament massive 
(AMM) répétée en Gambie sur le portage du Streptococcus pneumoniae 
dans le nasopharynx et sur l’émergence de souches résistantes aux 
antibiotiques.
Méthodes Cette étude a impliqué des villages qui ont participé à 
un essai randomisé par grappes, comparant l’effet d’un cycle d’AMM 
d’azithromycine par rapport à 3 cycles d’AMM d’azithromycine sur la 
prévalence du trachome. Seuls les villages dans lesquels la plupart des 
enfants ont reçu le vaccin antipneumococcique conjugué heptavalent 
ont été inclus dans l’étude. Trois études transversales ont été menées 
dans 2 villages ayant reçu 3 cycles d’AMM: la première étude juste 
avant la troisième AMM, et les deuxième et troisième études 1 et 
6 mois, respectivement, après la troisième AMM. La troisième étude a 
également couvert 6 villages qui avaient reçu une seule AMM 30 mois 
auparavant. Le portage pneumococcique a été évalué par le biais de 
prélèvements nasopharyngés, et la résistance à l’azithromycine a été 
détectée à l’aide de l’Etest.
Résultats La prévalence du portage pneumococcique a diminué 
de 43,4% à 19,2% entre la première et la deuxième étude (P < 0,001), 
mais elle a rebondi à la troisième étude (45,8%; P = 0,591). Le fait d’être 
porteur lors de la première étude était un facteur de risque pour être 
porteur lors de la deuxième étude (rapport des cotes: 3,71; P < 0,001). 
Dans la troisième étude, la prévalence du portage était similaire après 
un et 3 cycles d’AMM (50,3% contre 45,8%, respectivement; P = 0,170). 
Il en est de même pour la prévalence de la résistance à l’azithromycine 
(0,3% contre 0,9%, respectivement; P = 0,340).
Conclusion Trois cycles d’AMM n’augmentent pas la prévalence 
du portage de souches Streptococcus pneumoniae résistantes à 
l’azithromycine dans le nasopharynx, par rapport à un seul cycle.
Резюме
Массовое назначение азитромицина и носительство пневмококков: перекрестные исследования в 
Гамбии
Цель Оценить влияние повторного массового применения 
препарата (МПП) азитромицина в Гамбии на носоглоточное 
носительство пневмококков и возникновение штаммов, 
устойчивых к антибиотикам.
Методы Данное исследование охватывало деревни, участвующие 
в кластерном рандомизированном исследовании, в котором 
сравнивался эффект одного против трех циклов массового 
применения препарата азитромицина на распространенность 
трахомы. В исследование были включены только те деревни, 
в которых большинство детей получало семивалентную 
пневмококковую конъюгированную вакцину. Было проведено 
три перекрестных исследования в двух деревнях, принимавших 
три ежегодных курса МПП: первое исследование было проведено 
сразу перед третьим курсом МПП, а второе и третье – через 1 и 6 
месяцев соответственно, после завершения третьего курса МПП. 
В третье исследование также было включено шесть деревень, в 
которых прием одного курса МПП был осуществлен 30 месяцами 
ранее. Носительство пневмококковой инфекции оценивалось с 
помощью мазков из носоглотки, а устойчивость к азитромицину 
— с помощью Е-тестов.
Результаты Распространенность носительства пневмококков 
снизилась с 43,4% до 19,2% между первым и вторым 
исследованиями (P < 0,001), но вновь повысилась к третьему 
исследованию (45,8%, P = 0,591). Носитель в первом исследовании 
являлся фактором риска для носительства во втором 
исследовании (отношение рисков: 3,71; P <  0,001). В третьем 
исследовании распространенность носительства была 
аналогичной после одного и трех курсов МПП (50,3% против 
45,8% соответственно, P =  0,170), как и распространенность 
устойчивости к азитромицину (0,3% против 0,9% соответственно, 
P =  0,340).
Вывод Три курса МПП азитромицина не приводили к 
увеличению распространенности носоглоточного носительства 
пневмококковых штаммов, резистентных к азитромицину, по 
сравнению с первым курсом МПП.
Resumen
La administración en masa de la azitromicina y el transporte del Streptococcus pneumoniae: encuestas transversales en Gambia
Objetivo Evaluar el efecto de una administración masiva repetida 
(MDA) de azitromicina en Gambia sobre el transporte nasofaríngeo del 
Streptococcus pneumoniae y sobre la aparición de cepas resistentes a 
los antibióticos.
Métodos Este estudio involucró a pueblos que participaron en un 
ensayo aleatorio por grupos que comparó el efecto de una MDA 
de azitromicina de una sola ronda frente a una MDA de tres rondas 
sobre la prevalencia del tracoma. Solo se incluyeron aquellos pueblos 
en los que la mayoría de niños habían recibido la vacuna conjugada 
antineumocócica 7-valente. Se realizaron tres encuestas transversales 
en dos pueblos que recibieron tres rondas anuales de MDA: la primera 
inmediatamente antes de la tercera ronda de MDA y la segunda y la 
tercera, 1 y 6 meses, respectivamente, después de la tercera ronda de 
MDA. La tercera encuesta también incluyó seis pueblos que habían 
recibido una ronda de MDA 30 meses antes. Se evaluó el transporte 
neumocócico por medio de frotis nasofaríngeos y se detectó la 
resistencia a la azitromicina por medio del Etest.
Resultados La prevalencia del transporte neumocócico disminuyó 
del 43,4 % al 19,2 % entre la primera y la segunda encuesta (P < 
0,001), pero se recuperó en el momento de la tercera encuesta (45,8 
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%; P = 0,591). Ser portador en la primera encuesta fue un factor 
de riesgo para seguir siendo portador de la segunda (cociente de 
posibilidades: 3,71; P <  0,001). En la tercera encuesta, la prevalencia 
del transporte fue similar tras una y tres rondas de MDA (50,3 % frente 
a 45,8 %, respectivamente; P = 0,170), al igual que la prevalencia de 
la resistencia a la azitromicina (0,3 % frente a 0,9 %, respectivamente; 
P = 0,340).
Conclusión Las tres rondas de MDA de azitromicina no aumentaron 
la prevalencia del transporte nasofaríngeo de cepas de S. pneumoniae 
resistentes a la azitromicina en comparación con una única ronda.
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